Direct detection of respiratory syncytial virus, parainfluenza virus, and adenovirus in clinical respiratory specimens by a multiplex reverse transcription-PCR assay.
Diagnosis of respiratory virus infections currently involves detection by isolation or antigen detection, which usually identifies only a single suspected agent. To permit identification of more than one respiratory virus in clinical specimens, a rapid detection method involving a single-step, multiplex reverse transcription-PCR (RT-PCR) assay was developed. The assay included five primer sets that amplified the RNA of respiratory syncytial virus subtypes A and B, parainfluenza virus types 1, 2, and 3, and adenovirus types 1 to 7. Initially the assay was tested on tissue culture-grown virus and was found to be specific for all 12 prototype viruses tested, with no interassay cross amplification or amplification of other respiratory viruses. Assay sensitivity allowed a detection range of 0.2 50% tissue culture infectious dose (TCID50) for adenovirus to 250 TCID50 for parainfluenza virus type 1. The multiplex RT-PCR assay was also able to directly detect viruses in respiratory specimens, with virus being detected in 41 of 112 samples as compared to 34 of 112 samples detected by direct immunofluorescence or antigen detection following specimen culture. This suggests that the multiplex RT-PCR assay can be used as a rapid and sensitive diagnostic method for major respiratory viruses.
Influenza and Respiratory Viruses, Bureau of Microbiology, Laboratory Center for Disease Control, Federal Laboratories, Winnipeg, Manitoba R3M 3R2, Canada. carla_osiowy@hc-sc.gc.ca
C
C
Osiowy
D000258:Adenovirus Infections, Human / Q000175:diagnosis / Q000821:virology; D000260:Adenoviruses, Human / Q000235:genetics* / Q000276:immunology / Q000302:isolation & purification*; D000956:Antigens, Viral / Q000302:isolation & purification; D001483:Base Sequence; D002648:Child; D017931:DNA Primers / Q000235:genetics; D006801:Humans; D010222:Parainfluenza Virus 1, Human / Q000235:genetics* / Q000276:immunology / Q000302:isolation & purification*; D010223:Parainfluenza Virus 2, Human / Q000235:genetics* / Q000276:immunology / Q000302:isolation & purification*; D010224:Parainfluenza Virus 3, Human / Q000235:genetics* / Q000276:immunology / Q000302:isolation & purification*; D012367:RNA, Viral / Q000235:genetics / Q000302:isolation & purification; D018357:Respiratory Syncytial Virus Infections / Q000175:diagnosis / Q000821:virology; D012136:Respiratory Syncytial Viruses / Q000235:genetics* / Q000276:immunology / Q000302:isolation & purification*; D012141:Respiratory Tract Infections / Q000175:diagnosis* / Q000821:virology*; D010253:Respirovirus Infections / Q000175:diagnosis / Q000821:virology; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000379:methods* / Q000706:statistics & numerical data; D019351:Rubulavirus Infections / Q000175:diagnosis / Q000821:virology; D012680:Sensitivity and Specificity
D000956:Antigens, Viral; D017931:DNA Primers; D012367:RNA, Viral